Elicio Therapeutics Reports Narrowed Net Loss for Third Quarter
Elicio Therapeutics (ELTX) reported its third-quarter financial results, highlighting a significant reduction in net loss. The company's net loss per share improved to $0.30, compared to $0.60 in the same period last year, representing a 20.9% year-over-year narrowing of total net losses to $8.0 million. Operational costs showed mixed results as research and development expenses decreased by 3% to $4.9 million, while general and administrative expenses rose by 18.5% to $3.6 million. Total operating expenses increased slightly by 5.1% year-over-year. As of September 30, 2026, the company maintained a cash position of $30.9 million.
Tickers: $ELTX
Topics: cash position net loss operating expenses r&d expenses
Read the full article at Seeking Alpha
Part of the story Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026 (11 articles)